Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma. No US Food and Drug Administration–approved targeted antifibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aHSCs, while preserving quiescent HSCs and other normal cells, is a logical strategy to stop and/or reverse liver fibrogenesis/fibrosis. However, there are no effective approaches to specifically deplete aHSCs during fibrosis without systemic toxicity. aHSCs are associated with elevated expression of death receptors and become sensitive to tumor necrosis factor–related apoptosis‐inducing ligand (TRAIL)‐induced cell death. Treatment with recombinant TRAIL could be a potential strategy to ameliorate liver fibrosis; however, the therapeutic application of recombinant TRAIL is halted due to its very short half‐life. To overcome this problem, we previously generated PEGylated TRAIL (TRAIL PEG) that has a much longer half‐life in rodents than native‐type TRAIL. In this study, we demonstrate that intravenous TRAIL PEG has a markedly extended half‐life over native‐type TRAIL in nonhuman primates and has no toxicity in primary human hepatocytes. Intravenous injection of TRAIL PEG directly induces apoptosis of aHSCs in vivo and ameliorates carbon tetrachloride‐induced fibrosis/cirrhosis in rats by simultaneously down‐regulating multiple key fibrotic markers that are associated with aHSCs.Conclusion: TRAIL‐based therapies could serve as new therapeutics for liver fibrosis/cirrhosis and possibly other fibrotic diseases. (H epatology 2016;64:209–223)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“TGF-b and PDGF-R are typically produced by platelets and Kupffer cells/macrophages during the early stages of liver damage; however, after activation of HSCs, aHSCs become the major source of these cytokines, which act in an autocrine manner to promote further HSC activation, cell migration, and ECM formation.((28,34)…”
BackgroundEffect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 2×
“In addition, PEGylated proteins are considered less immunogenic than their non-PEGylated counterparts.((17)) Some clinical concerns have been raised for high molecular weight PEGylated protein drugs, but clinical doses are drastically lower than those demonstrated for PEG toxicity.”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 2×
“Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a type 2 transmembrane protein in the TNF-a superfamily due to sequence homology with TNF and FasL.((8,9)) TRAIL can be proteolytically cleaved from the cell surface and released in soluble form.”
BackgroundMolecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382 · cited 1×
“In addition, receptor-activating protein 1, a kinase involved in necroptosis (programmed necrosis),((24)) was up-regulated in aHSCs (Fig.”
BackgroundLiver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Hepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719 · cited 1×
“Because TRAIL-induced apoptosis has been predominantly investigated in cancer cells and not in primary human HSCs, we are currently exploring mechanisms of TRAIL resistance and sensitivity by comparing TRAIL death pathways between HSCs and cancer cells.((37)) TRAILPEG could also target cirrhosisassociated hepatocellul…”
BackgroundAlcoholic liver disease: pathogenesis and new targets for therapy
Altamirano, J., & Bataller, R. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.134 · Cited by 284
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.024 · Cited by 260
Koda, Y., Teratani, T., Chu, P.-S., Hagihara, Y., Mikami, Y., Harada, Y., Tsujikawa, H., Miyamoto, K., Suzuki, T., Taniki, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24734-0 · Cited by 219
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“Once toxic liver damage is halted, activated HSCs evade apoptosis, reduce their expression of fibrogenic genes, and differentiate into quiescent HSC states [189–193].”
BackgroundIt’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
Khurana, A., Sayed, N., Allawadhi, P., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-2948 · Cited by 79
Crosstalk between NK cells and hepatic stellate cells in liver fibrosis (Review)
Zhang, Y., Wu, Y., Shen, W., Wang, B., & Yuan, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12724 · Cited by 35
Feng, D. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.003 · Cited by 18
Metadata
- Authors
- Oh, Y., Park, O., Swierczewska, M., Hamilton, J. P., Park, J., Kim, T. H., Lim, S., Eom, H., Jo, D. G., Lee, C., Kechrid, R., Mastorakos, P., Zhang, C., Hahn, S. K., Jeon, O., Byun, Y., Kim, K., Hanes, J., Lee, K. C., Pomper, M. G., Gao, B., & Lee, S.
- Venue
- Hepatology
- Published
- 2016-03-03
- Volume
- 64
- Issue
- 1
- Pages
- 209-223
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2256403975
- Cited by
- 77
- References
- 9
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.